SEARCH

SEARCH BY CITATION

References

  • Akiyama H. and McGeer P. L. (1989) Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. 489, 247253.
  • Bal-Price A. and Brown G. C. (2001) Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J.Neurosci. 21, 64806491.
  • Bernardo A., Levi G. and Minghetti L. (2000) Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-delta12,14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 12, 22152223.
  • Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y. and Hirsch E. C. (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172, 151154.
  • Chao C. C., Hu S., Molitor T. W., Shaskan E. G. and Peterson P. K. (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J. Immunol. 149, 27362741.
  • Combs C. K., Johnson D. E., Karlo J. C., Cannady S. B. and Landreth G.E. (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20, 558567.
  • Cullingford T. E., Bhakoo K., Peuchen S., Dolphin C. T., Patel R. and Clark J. B. (1998) Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem. 70, 13661375.
  • Dehmer T., Lindenau J., Haid S., Dichgans J. and Schulz J. B. (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74, 22132216.
  • Delerive P., Fruchart J. C. and Staels B. (2001) Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169, 453459.
  • Feinstein D. L., Brosnan C. F., Sharp A., Landreth G. E., Gavrilyuk V., Wullner U. and Heneka M. T. (2001) Suppression of experimental autoimmune encephalomyelitis by pioglitazone, a PPAR-gamma agonist. Soc. Neurosci. Abstracts 27 , 102.15.
  • Franklin K. B. J. and Paxinos G. (1996) The Mouse Brain in Stereotaxic Coordinates. Academic Press, Sydney.
  • Ghulam N., Sager T., Laursen H. and Vaudano E. (2001) Minocycline reduces microglia activation in the chronic MPTP mouse model of Parkinson's disease. Soc. Neurosci. Abstracts 27 , 887.8.
  • He B. P., Tay S. S. and Leong S. K. (1997) Microglia responses in the CNS following sciatic nerve transection in C57BL/Wld(s) and BALB/c mice. Exp. Neurol. 146, 587595.
  • He Y., Appel S. and Le W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909, 187193.
  • Heneka M. T., Klockgether T. and Feinstein D. L. (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J.Neurosci. 20, 68626867.
  • Hirsch E. C. (2000) Glial cells and Parkinson's disease. J. Neurol. 247, II58II62.
  • Hirsch E., Graybiel A. M. and Agid Y. A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345348.
  • Hunot S., Boissière F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y. and Hirsch E. C. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72, 355363.
  • Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M. P., Ruberg M., Faucheux B. A., Agid Y. and Hirsch E. C. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl Acad. Sci. USA 94, 75317536.
  • Jackson-Lewis V., Jakowec M., Burke R. E. and Przedborski S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257269.
  • Jiang C., Ting A. T. and Seed B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 8286.
  • El-Kebbi I. M., Roser S. and Pollet R. J. (1994) Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43, 953958.
  • Kim W. G., Mohney R. P., Wilson B., Jeohn G. H., Liu B. and Hong J. S. (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20, 63096316.
  • Kreutzberg G. W. (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19, 312318.
  • Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A. and Czlonkowska A. (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156, 5061.DOI: 10.1006/exnr.1998.6993
  • Langston J. W., Forno L. S., Tetrud J., Reeves A. G., Kaplan J. A. and Karluk D. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598605.DOI: 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F
  • Lawson L. J., Perry V. H., Dri P. and Gordon S. (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39, 151170.
  • Le W., Rowe D., Xie W., Ortiz I., He Y. and Appel S. H. (2001) Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21, 84478455.
  • Li M., Pascual G. and Glass C. K. (2000) Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell Biol. 20, 46994707.
  • Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., McAuliffe W. G., Dawson V. L., Dawson T. M. and Przedborski S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 14031409.
  • Liu B., Jiang J. W., Wilson B. C., Du L., Yang S. N., Wang J. Y., Wu G.C., Cao X. D. and Hong J. S. (2000) Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J. Pharmacol. Exp. Ther. 295, 125132.
  • Lu X., Bing G. and Hagg T. (2000) Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons inadult rats. Neuroscience 97, 285291.
  • Maeshiba Y., Kiyota Y., Yamashita K., Motohashi M. and Tanayama S. (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneim-Forschung/Drug Res. 47, 2935.
  • McGeer P. L., Itagaki S., Boyes B. E. and McGeer E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra ofParkinson's and Alzheimer's disease brains. Neurology 38, 12851291.
  • Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M. and Nagatsu T. (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147150.
  • Palacios J. M. and Wiederhold K. H. (1984) Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2–14C] deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains. Brain Res. 301, 187191.
  • Palombo E., Porrino L. J., Bankiewicz K. S., Crane A. M., Kopin I. J. and Sokoloff L. (1988) Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. Brain Res. 453, 227234.
  • Przedborski S. and Jackson-Lewis V. (1998) Mechanisms of MPTP toxicity. Mov Disord 13, 3538.
  • Ricote M., Li A. C., Willson T. M., Kelly C. J. and Glass C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 7982.
  • Smith U. (2001) Pioglitazone: mechanism of action. Int. J. Clin. Pract. supplement 13–18.
  • Sokoloff L. (1993) Sites and mechanisms of function-related changes in energy metabolism in the nervous system. Dev. Neurosci. 15, 194206.
  • Takamura T., Ando H., Nagai Y., Yamashita H., Nohara E. and Kobayashi K. (1999) Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res. Clin. Pract 44, 107114.
  • Tang Y., Osawa H., Onuma H., Nishimiya T., Ochi M. and Makino H. (1999) Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 48, 18301835.
  • Viale G., Gambacorta M., Coggi G., Dell'Orto P., Milani M. and Doglioni C. (1991) Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast. Virchows Arch. A Pathol. Anat. Histopathol. 418, 339348.
  • Vodovotz Y., Bogdan C., Paik J., Xie Q. W. and Nathan C. (1993) Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med. 178, 605613.